Eli Lilly extended its collaboration with Nimbus Therapeutics to develop an oral obesity therapy, committing $55 million in upfront and near‑term payments and potential downstream milestones that could total about $1.3 billion. Nimbus will apply its computational chemistry and structure‑based design engine to identify small‑molecule candidates, with Lilly holding an exclusive worldwide license. The partnership reprises an earlier metabolic collaboration between the firms and underscores Big Pharma’s continuing push into oral obesity agents. Nimbus will receive R&D funding and is eligible for development and commercial milestones plus tiered royalties if a program advances to market.